��������

Jeffrey Bartlett is an accomplished biotechnology professional with extensive expertise in gene therapy and molecular virology. Currently serving as CTO/CIO and Co-Founder at Rampart Bioscience since January 2020, Jeffrey previously held significant roles including Senior Director of Gene Therapy Strategic Development at CSL Behring from September 2017 to October 2023, and Chief Scientific Officer at Calimmune, Inc., where leadership in global R&D programs was emphasized. As Vice President of Research & Development at The Ohio State University, Jeffrey focused on the advancement of cell and gene therapies. An academic background includes positions as Associate Professor in Pediatrics and Molecular Virology, contributing to research in gene transfer technologies and viral vectors. Education credentials include a Ph.D. in Molecular Biology from the University of Pittsburgh School of Medicine and an A.B. in Biology and Art from Middlebury College.